1
|
Ellis RJ, Zhou EH, Fu P, Kaminsky DA, Sodee DB, Faulhaber PF, Bodner D, Resnick MI. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure. J Urol 2008; 179:1768-73; discussion 1773-4. [PMID: 18343445 DOI: 10.1016/j.juro.2008.01.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2007] [Indexed: 11/16/2022]
Abstract
PURPOSE We evaluate the usefulness of pretreatment (111)Indium capromab pendetide (ProstaScint) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. MATERIALS AND METHODS Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). RESULTS Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. CONCLUSIONS Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.
Collapse
Affiliation(s)
- R J Ellis
- Department of Radiation Oncology, Aultman Hospital, Canton, Ohio, USA.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Ellis RJ, Zhou H, Kaminsky DA, Fu P, Kim EY, Sodee DB, Colussi V, Spirnak JP, Whalen CC, Resnick MI. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. Brachytherapy 2007; 6:149-56. [PMID: 17434109 DOI: 10.1016/j.brachy.2007.01.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2006] [Revised: 01/19/2007] [Accepted: 01/19/2007] [Indexed: 11/28/2022]
Abstract
PURPOSE To evaluate rectal morbidity after dose escalation to biologic target volumes identified by capromab pendetide (ProstaScint) single-photon emission tomography images coregistered with computed tomography (SPECT/CT). METHODS AND MATERIALS Two hundred thirty-nine consecutive patients diagnosed with T1c-T3b NxM0 adenocarcinoma of the prostate were treated with brachytherapy seed implant (SI) dose escalation to SPECT/CT-identified biologic target volumes, from February 1997 through December 2002. Patients received SI (n=150) or external beam radiation therapy plus SI (n=89). Rectal morbidity was evaluated by clinician scoring using the modified Radiation Therapy Oncology Group criteria. The median followup was 47.2 (range 24.8-96.1) months. RESULTS The rate of acute Grades I and II toxicity was 29.9% and 3.7%, respectively, and chronic Grade I toxicity was 15.4%, 12.4%, 2.3%, and 1.8% at 1, 2, 3, and 4 years postimplant, respectively. Chronic Grade II toxicities were 1.8%, 1.9%, 1.5%, and 0.9% at 1, 2, 3, and 4 years, respectively. No Grade III rectal toxicity was reported. Chronic Grade IV rectal toxicity was 0.5% and 0.6% at 1.5 and 2.5 years, respectively. Ninety-six percent of patients reported freedom from all rectal toxicity after 3 years. CONCLUSIONS Dose intensification to occult tumor targets without increasing rectal toxicity may be achieved using SPECT/CT ProstaScint. Additional research to define the role of molecular imaging in prostate cancer is warranted.
Collapse
Affiliation(s)
- Rodney J Ellis
- Department of Radiation Oncology, Aultman Hospital, Canton, OH, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sodee DB, Sodee AE, Bakale G. Synergistic Value of Single-Photon Emission Computed Tomography/Computed Tomography Fusion to Radioimmunoscintigraphic Imaging of Prostate Cancer. Semin Nucl Med 2007; 37:17-28. [PMID: 17161036 DOI: 10.1053/j.semnuclmed.2006.07.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The rationale on which positron emission tomography/computed tomography (PET/CT) imaging is based, combining the functional features of PET with the anatomic detail of CT, provides many advantages that are easily transferable to single-photon emission computed tomography (SPECT)/CT imaging. Our efforts have focused on applying fused SPECT/CT imaging to identify prostate cancer and its metastasis and recurrence through radioimmunoscintigraphy (RIS). This application of RIS to imaging prostate cancer requires 2 key components: (1) a well-defined target associated with the cancer and (2) a "magic bullet" to seek that target. A well-characterized RIS target for prostate cancer is prostate-specific membrane antigen, or PSMA, and finding the bullet to seek this target with high sensitivity and specificity has been the focus of intensive study for nearly two decades. One of the candidate bullets developed is capromab pendetide, which is a monoclonal antibody that seeks PSMA. This antibody is commercially available as ProstaScint, which can be labeled with indium-111 to localize prostate cancer via SPECT imaging. In the course of applying fused SPECT/CT ProstaScint imaging to more than 800 prostate cancer cases, numerous refinements to our protocol have evolved that are aimed at staging the cancer with utmost accuracy. In addition to optimizing the localization of prostate cancer and its metastasis, these refinements also have been extended toward guiding both the implantation of radioactive seeds in brachytherapy and in other types of radiation therapy which is illustrated through 5 case reports. Progress in the therapeutic targeting of PSMA is also being actively explored, which has more universal ramifications because PSMA is found in the neovasculature of other types of cancers.
Collapse
Affiliation(s)
- D Bruce Sodee
- Department of Radiology, Division of Nuclear Medicine, University Hospitals of Cleveland and Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
| | | | | |
Collapse
|
4
|
Abstract
Nuclear imaging with In-111-labeled leukocytes has become an instrumental tool in localizing sites of infection and is superior to Ga-67 in localizing abdominal and pelvic abscesses resulting from absence of a normal bowel excretory pathway. Labeled white blood cells (WBCs) localize at sites of infection through diapedesis, chemotaxis, and enhanced vascular permeability and can thus be used to identify infection. The accuracy of this functional imaging modality can be enhanced by fusing SPECT images of labeled WBC with CT images that provide anatomic detail to facilitate reading as illustrated in the case described.
Collapse
Affiliation(s)
- Jennifer Nathan
- University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Department of Radiology, Division of Nuclear Medicine, Cleveland, Ohio 44106, USA
| | | | | | | |
Collapse
|
5
|
Proaño JM, Sodee DB, Resnick MI, Einstein DB. The Impact of a Negative
111
Indium-Capromab Pendetide Scan Before Salvage Radiotherapy. J Urol 2006; 175:1668-72. [PMID: 16600726 DOI: 10.1016/s0022-5347(05)00982-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2005] [Indexed: 11/16/2022]
Abstract
PURPOSE We determined the prognostic role, if any, of the ProstaScint (111)indium-capromab pendetide scan before salvage radiotherapy for biochemical recurrence after RP for localized prostate cancer. MATERIALS AND METHODS We reviewed the records of 649 patients who underwent a ProstaScint scan from 1998 to 2004. A total of 44 patients were identified who had biochemical recurrence after RP and underwent a ProstaScint scan immediately before salvage radiotherapy. All patients received salvage radiotherapy to the prostatic bed unless pelvic lymph node uptake was identified on the scan, resulting in initial whole pelvic radiotherapy with 45 Gy, followed by a conformal boost to the prostate bed in 6. The median salvage radiotherapy dose to the prostate bed was 72 Gy. Patient demographics, pathological information, PSA values and ProstaScint results were collected retrospectively. The majority of ProstaScint scans were digitally fused with noncontrast pelvic computerized tomography images for interpretation. PSA progression after radiotherapy was defined using American Society for Therapeutic Radiation and Oncology criteria. RESULTS At a mean followup of 22 months 43 of 44 patients (97%) experienced a PSA decrease after salvage radiotherapy with a mean PSA nadir of 0.16 ng/ml compared to a mean pre-radiotherapy PSA of 1.7 ng/ml. Of the 44 patients 15 (34%) showed post-radiotherapy PSA progression. When the entire cohort was analyzed, patients with negative ProstaScint scans had statistically lower post-radiotherapy PSA progression rates than patients with positive scans (1 of 10 or 10% vs 14 of 34 or 41%, p = 0.026). Patients with negative ProstaScint results were also statistically more likely to have a pre-radiotherapy PSA of less than 1.0 ng/ml (p = 0.005), no seminal vesicle involvement (p = 0.006), a greater mean PSA doubling time (p = 0.008) and received no hormone therapy (p = 0.003). When patients with pre-radiotherapy PSA less than 1.0 ng/ml were analyzed, a negative ProstaScint scan suggested but did not provide a statistically significant advantage over pre-radiotherapy PSA alone for predicting post-radiotherapy PSA progression (1 of 9 or 11% for negative vs 5 of 15 or 33% for positive scans, p = 0.20). CONCLUSIONS Our early experience supports an improved prognosis in patients receiving salvage pelvic radiotherapy for biochemical recurrence after RP who have a negative pre-radiotherapy ProstaScint scan. However, this finding is not necessarily independent of pre-radiotherapy PSA.
Collapse
Affiliation(s)
- Juan M Proaño
- Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA
| | | | | | | |
Collapse
|
6
|
Ellis RJ, Zhou H, Fu P, Waseet V, Sodee DB, Kaminsky D, Kim C, Resnick MI. 1649: Spectict Capromab Pendetide Independently Predicts BDFS in Long Term Outcome Study. J Urol 2006. [DOI: 10.1016/s0022-5347(18)33841-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Lee Z, Sodee DB, Resnick M, Maclennan GT. Multimodal and three-dimensional imaging of prostate cancer. Comput Med Imaging Graph 2005; 29:477-86. [PMID: 15893911 DOI: 10.1016/j.compmedimag.2005.01.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2004] [Revised: 11/18/2004] [Accepted: 01/11/2005] [Indexed: 01/29/2023]
Abstract
Accurate characterization of prostate cancer is crucial for treatment planning and patient management. Non-invasive SPECT imaging using a radiolabeled monoclonal antibody, 111In-labeled capromab pendetide, offers advantage over existing means for prostate cancer diagnosis and staging. However, there are difficulties associated with the interpretation of these SPECT images. In this study, we developed a 3D surface-volume hybrid rendering method that utilizes multi-modality image data to facilitate diagnosis of prostate cancer. SPECT and CT or MRI (or both) images were aligned either manually or automatically. 3D hybrid rendering was implemented to blend prostate tumor distribution from SPECT in pelvis with anatomic structures from CT/MRI. Feature extraction technique was also implemented within the hybrid rendering for tumor uptake enhancement. Autoradiographic imaging and histological evaluation were performed to correlate with the in-vivo SPECT images. Warping registration of histological sections was carried out to compensate the deformation of histology slices during fixation to help the alignment between histology and in-vivo images. Overall, the rendered volumetric evaluation of prostate cancer has the potential to greatly increase the confidence in the reading of radiolabeled monoclonal antibody scans, especially in patients where there is a high suspicion of prostate tumor metastasis.
Collapse
Affiliation(s)
- Zhenghong Lee
- Division of Nuclear Medicine, Department of Radiology, Case Western Reserve University, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106, USA.
| | | | | | | |
Collapse
|
8
|
Abstract
The primary objective of this overview is to apprise clinical urologists and oncologists of the current state of fused multimodality imaging of prostate cancer, which can be applied to optimize treatment by ensuring that a patient's disease is characterized as well as current imaging technology permits. The focus of this study is the monoclonal antibody capromab pendetide, which targets prostate specific membrane antigen (PSMA), a type II membrane glycoprotein strongly associated with prostate cancer. Identifying where capromab pendetide uptake occurs can be done accurately if this functional imaging modality is combined with a modality that provides anatomic detail, such as computed tomography (CT) or magnetic resonance imaging (MRI). Image fusion, or coregistration, which is overlaying the functional images of capromab pendetide uptake on the anatomic CT or MRI images, provides a detailed map of cancer localization inside and outside the prostate gland. This same principle of fusing functional images on anatomic images is the basis for enormous growth of positron emission tomography with CT during the past 2 years. Positron emission tomography imaging has a different functionality base than does capromab pendetide, and thus the 2 modalities should be complementary. However, the key to both functional imaging modalities is accurate fusion with anatomic images, which is illustrated in our case reports. The cases cited demonstrate the need to optimize every phase of imaging from patient preparation to reading and reporting increased PSMA concentration seen on the fused images. Reference is also made to applying capromab pendetide/CT fused imaging to radiation therapy planning.
Collapse
Affiliation(s)
- D Bruce Sodee
- Department of Radiology, Division of Nuclear Medicine, University Hospitals of Cleveland/Case University School of Medicine, OH 44106, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Fei B, Duerk JL, Sodee DB, Wilson DL. Semiautomatic nonrigid registration for the prostate and pelvic MR volumes. Acad Radiol 2005; 12:815-24. [PMID: 16039535 DOI: 10.1016/j.acra.2005.03.063] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2004] [Revised: 03/14/2005] [Accepted: 03/15/2005] [Indexed: 11/22/2022]
Abstract
RATIONALE AND OBJECTIVES Three-dimensional (3D) nonrigid image registration for potential applications in prostate cancer treatment and interventional magnetic resonance (iMRI) imaging-guided therapies were investigated. MATERIALS AND METHODS An almost fully automated 3D nonrigid registration algorithm using mutual information and a thin plate spline (TPS) transformation for MR images of the prostate and pelvis were created and evaluated. In the first step, an automatic rigid body registration with special features was used to capture the global transformation. In the second step, local feature points (FPs) were registered using mutual information. An operator entered only five FPs located at the prostate center, left and right hip joints, and left and right distal femurs. The program automatically determined and optimized other FPs at the external pelvic skin surface and along the femurs. More than 600 control points were used to establish a TPS transformation for deformation of the pelvic region and prostate. Ten volume pairs were acquired from three volunteers in the diagnostic (supine) and treatment positions (supine with legs raised). RESULTS Various visualization techniques showed that warping rectified the significant pelvic misalignment by the rigid-body method. Gray-value measures of registration quality, including mutual information, correlation coefficient, and intensity difference, all improved with warping. The distance between prostate 3D centroids was 0.7 +/- 0.2 mm after warping compared with 4.9 +/- 3.4 mm with rigid-body registration. CONCLUSION Semiautomatic nonrigid registration works better than rigid-body registration when patient position is changed greatly between acquisitions. It could be a useful tool for many applications in the management of prostate.
Collapse
Affiliation(s)
- Baowei Fei
- Department of Radiology, Case Western Reserve University and University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
| | | | | | | |
Collapse
|
10
|
Ellis RJ, Kim ED, Zhou H, Fu P, Einstein D, Colussi V, Sodee DB, Spirnak JP, Dinchman KH, Kinsella TJ, Resnick MI. 1071: Rectal Toxicity following Permanent Prostate Brachytherapy with Dose Escalation to Biological Tumor Volumes (BTV) Identified with Prostascint and CT Scan Image Fusion. J Urol 2004. [DOI: 10.1016/s0022-5347(18)38308-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Sodee DB, Faulhaber PF, Nelson AD, Bakale G. The Prognostic Significance of Indium-111–Capromab Penetide. J Clin Oncol 2004; 22:379-80; author reply 380-1. [PMID: 14722051 DOI: 10.1200/jco.2004.99.163] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Abstract
RATIONALE AND OBJECTIVES To aid in surgical and radiation therapy planning for prostate adenocarcinoma, a general-purpose automatic registration method that is based on mutual information was used to align magnetic resonance (MR) images and single photon emission computed tomographic (SPECT) images of the pelvis and prostate. MATERIALS AND METHODS The authors assessed the effects of various factors on alignment between pairs of MR and SPECT images, including the use of particular pulse sequences in MR imaging, image voxel intensity scaling, the use of different regions on the MR-SPECT histogram, spatial masking of nonoverlapping visual data between images, and multiresolution optimization. A mutual information algorithm was used as the cost function for automatic registration. Automatic registration was deemed acceptable when it resulted in a transformation with less than 2 voxel units (6 mm) difference in translation and less than 2 degree difference in rotation from that obtained with manual registration performed independently by nuclear medicine radiologists. RESULTS Paired sets of MR and SPECT image volumes from four of five patients were successfully registered. For successful registration, MR images must be optimal and registration must be performed at full spatial resolution and at the full intensity range. Masking, cropping, and the normalization of mutual information, used to register partially overlapping MR-SPECT volumes, were not successful. Multiresolution optimization had little effect on the accuracy and speed of the registration. CONCLUSION Automatic registration between MR and SPECT images of the pelvis can be achieved when data acquisition and image processing are performed properly. It should prove useful for prostate cancer diagnosis, staging, and treatment planning.
Collapse
Affiliation(s)
- Zhenghong Lee
- Department of Radiology, University Hospitals of Cleveland, School of Medicine, Cleveland, Ohio 44106, USA
| | | | | | | | | |
Collapse
|
13
|
Ellis RJ, Kim EY, Conant R, Sodee DB, Spirnak JP, Dinchman KH, Beddar S, Wessels B, Resnick MI, Kinsella TJ. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001; 49:1281-6. [PMID: 11286835 DOI: 10.1016/s0360-3016(00)01582-0] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE We have previously presented a technique that fuses ProstaScint and pelvic CT images for the purpose of designing brachytherapy that targets areas at high risk for treatment failure. We now correlate areas of increased intensity seen on ProstaScint-CT fusion images to biopsy results in a series of 7 patients to evaluate the accuracy of this technique in localizing intraprostatic disease. METHODS AND MATERIALS The 7 patients included in this study were evaluated between June 1998 and March 29, 1999 at Metrohealth Medical Center and University Hospitals of Cleveland in Cleveland, Ohio. ProstaScint and CT scans of each patient were obtained before transperineal biopsy and seed implantation. Each patient's prostate gland was biopsied at 12 separate sites determined independently of Prostascint-CT scan results. RESULTS When correlated with biopsy results, our method yielded an overall accuracy of 80%: with a sensitivity of 79%, a specificity of 80%, a positive predictive value of 68%, and a negative predictive value of 88%. CONCLUSION The image fusion of the pelvic CT scan and ProstaScint scan helped identify foci of adenocarcinoma within the prostate that correlated well with biopsy results. These data may be useful to escalate doses in regions containing tumor by either high-dose rate or low-dose rate brachytherapy, as well as by external beam techniques such as intensity modulated radiotherapy (IMRT).
Collapse
Affiliation(s)
- R J Ellis
- Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000; 56:988-93. [PMID: 11113745 DOI: 10.1016/s0090-4295(00)00824-4] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
OBJECTIVES To report the results of a retrospective study of 2290 ProstaScint scans of 2154 patients with prostate carcinoma done at 15 institutions. METHODS The results were analyzed by logistic regression after stratification of the patients into four groups: group 1, newly diagnosed; group 2, after radical prostatectomy with a rising prostate-specific antigen (PSA) level; group 3, after radiation therapy with a rising PSA level; and group 4, after hormonal therapy. RESULTS The PSA level and ProstaScint scans positive in the prostate bed (P <0.001) and for pelvic metastases (P <0.001), but not for extrapelvic metastases, correlated significantly in group 1 patients. In group 2, the association for detecting fossa recurrence was weaker (P = 0.033) and was insignificant for pelvic and extrapelvic metastases. Patients in group 3 also exhibited a weak PSA-ProstaScint association for detecting fossa recurrence (P = 0.038), and was insignificant for pelvic and extrapelvic metastases. No significant PSA-ProstaScint correlation was found in patients in group 4 for fossa recurrence, pelvic or extrapelvic metastases. The distribution of positive ProstaScint results among the prostate/prostate bed, pelvic nodes, and extrapelvic nodes was nearly equal for all groups, except that a significantly greater percentage of extrapelvic metastases was found in the hormonal group (group 4). The ProstaScint results were independent of the Gleason score for 260 patients before and 285 patients after therapy. CONCLUSIONS The results of this study underscore the complementary diagnostic value of ProstaScint to PSA level and Gleason score as an independent indicator of prostate cancer recurrence and metastases and in identifying extrapelvic metastases in both newly diagnosed and recurrent prostate cancer.
Collapse
Affiliation(s)
- D B Sodee
- Department of Radiology, University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, USA
| | | | | | | | | | | |
Collapse
|
15
|
Ellis RJ, Sodee DB, Spirnak JP, Dinchman KH, O'Leary AW, Samuels MA, Resnick MI, Kinsella TJ. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48:683-7. [PMID: 11020564 DOI: 10.1016/s0360-3016(00)00646-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE We present a technique that fuses pelvic CT scans and ProstaScint images to localize areas of disease within the prostate gland to customize prostate implants. Additionally, the acute toxicity results from the first 43 patients treated with this technique are reviewed. METHODS AND MATERIALS Between 2/97 and 8/98, 43 patients with clinical stage II prostate adenocarcinoma received ultrasound-guided transperineal implantation of I-125 or Pd-103 seeds. The median patient age was 70 years (range 49-79). Prior to treatment, the median Gleason score and prostate-specific antigen (PSA) were 6 (range 3-8) and 7.5 (range 1.8-16.6 ng/mL), respectively. The median follow-up was 10 months (range 2.9-20.4 months). RESULTS The median PSA value at 10 months is 0.7 ng/mL. Significant acute complications within the first month following implantation included 13 Grade I urinary symptoms, 24 Grade II urinary symptoms, 6 Grade III symptoms, and no Grade IV complications. Beyond 4 months, complications included 12 Grade I urinary symptoms, 17 Grade II urinary symptoms, 1 Grade III, and 1 Grade IV complications. CONCLUSIONS The image fusion of the pelvic CT scan and ProstaScint scans helped identify regions within the prostate at high risk of local failure, which were targeted with additional seeds during implantation.
Collapse
Affiliation(s)
- R J Ellis
- Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate 1998; 37:140-8. [PMID: 9792131 DOI: 10.1002/(sici)1097-0045(19981101)37:3<140::aid-pros3>3.0.co;2-q] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND ProstaScint (Cytogen Corporation, Princeton, NJ) murine monoclonal antibody imaging is FDA-approved for imaging of prostate cancer patients at high risk for metastatic disease and patients postprostatectomy with a rising serum prostate-specific antigen (PSA) level. ProstaScint is a murine monoclonal antibody which targets prostate-specific membrane antigen (PSMA). PSMA expression is upregulated in primary and metastatic prostate cancer. FDA Cytogen (Princeton, NJ) protocol studies using 111indium-labeled ProstaScint revealed correlation between areas of increased concentration in the prostate and biopsy-proven tumors in patients imaged pretherapy. METHODS In our study, four transverse, single-photon emission tomography (SPECT) images were isolated and regions of interest were selected and correlated with pretherapy prostate biopsy results. Prostate cancer and normal tissue prostate/muscle background (P/M) ratios were derived, so that postprostatectomy/radiation therapy patients could be evaluated for the presence of residual prostate cancer. Twenty-three pretherapy prostate cancer patients with quadrant/sextant biopsies had SPECT 96-hr 111indium ProstaScint pelvic images. The four transverse 1-cm slices above the midline penile blood pool were chosen, and four to six 27-30-pixel regions of interest were placed over the prostate bed. The background muscle region of interest was placed over the external obturator muscle region. The P/M ratio was calculated and compared to the quadrant/sextant prostatic biopsy result. The same procedure was applied to 17 posttherapy prostate cancer patients with rising PSA. RESULTS In the 23 pretherapy prostate cancer patients, there was a correlation between the P/M ratio of at least 3.0 in 32 of 35 prostatic cancer biopsy regions, and there was correlation with P/M ratios less than 3.0 in 82 of 89 negative biopsy regions. Seventeen posttherapy patients underwent ProstaScint studies. Six underwent biopsy, with typically one biopsy site per patient. All 6 had P/M ratios greater than 3.0 in the biopsied region. Five out of six biopsies revealed residual prostate cancer. CONCLUSIONS A prostate/muscle ratio was developed from 111indium ProstaScint regions of interest obtained on 1-cm SPECT transverse slices through the prostate bed in 23 patients preprostatic cancer therapy. A P/M ratio above 3.0 correlated in the majority of positive cases, and a P/M ratio below 3.0 was demonstrated in negative prostatic biopsy cases. The P/M ratio of above 3.0 or below 3.0 also separated those posttherapy prostate cancer patients with rising PSA who had residual prostate carcinoma in the prostate bed.
Collapse
Affiliation(s)
- D B Sodee
- Department of Radiology, MetroHealth Medical Center/Case Western Reserve University, Cleveland, Ohio, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 1996; 21:759-67. [PMID: 8896922 DOI: 10.1097/00003072-199610000-00002] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
To evaluate whether In-111 capromab pendetide (an antibody conjugate directed to a glycoprotein found primarily on the cell membrane of prostate tissue) radioimmunoscintigraphy can localize residual or metastatic prostatic carcinoma in 15 patients after prostatectomy and lymphadenectomy for prostatic carcinoma with rising serum prostate-specific antigen. One patient with 0.6 ng/ml serum prostate-specific antigen had normal imaging results and 14 patients had scintigraphic evidence of residual prostatic bed or metastatic prostatic carcinoma. Two patients with borderline abnormal bone scans had abnormal activity in the same regions on In-111 capromab pendetide images. All patients had negative radiographic abdominal and pelvic cross-sectional prestudy images, and there were no adverse effects related to In-111 capromab pendetide infusion and little human antimouse antibody response.
Collapse
Affiliation(s)
- D B Sodee
- Department of Radiology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109-1998, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Light VL, McHenry CR, Jarjoura D, Sodee DB, Miron SD. Prospective comparison of dual-phase technetium-99m-sestamibi scintigraphy and high resolution ultrasonography in the evaluation of abnormal parathyroid glands. Am Surg 1996; 62:562-7; discussion 567-8. [PMID: 8651552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Technetium-99m-sestamibi (MIBI) is a new radionuclide for imaging parathyroid tissue. The purpose of this study was to evaluate parathyroid localization using single radiotracer, dual-phase MIBI scintigraphy and to compare the results to ultrasonography. Twenty-one patients with hyperparathyroidism underwent dual-phase scintigraphy using 25 mCi MIBI and high resolution ultrasonography before parathyroidectomy. Scan results were correlated with size, weight, location, and histopathology of excised parathyroid glands, thyroid abnormalities, and cost. Seventeen patients were female, five had secondary or tertiary hyperparathyroidism, and three had a previous parathyroid exploration. Twenty patients (95%) were cured, 14 with a single and 1 with a double adenoma, and 5 of 6 patients with generalized hyperplasia. There were no false positive MIBI scans and one false positive ultrasound study, despite associated thyroid nodules in 29 per cent of patients. The sensitivity of MIBI and ultrasound in the identification of adenomas was 87 per cent versus 57 per cent (P = 0.046), and the rate of detection of hyperplastic glands was 44 per cent versus 24 per cent (P = 0.19), respectively. There was no correlation between scan results and size, weight, or location of adenomatous glands. The cost of dual-phase MIBI was comparable to that of ultrasound. Dual-phase MIBI is more sensitive than ultrasound in the localization of adenomas and is the preferable modality for preoperative parathyroid localization. Neither MIBI nor ultrasound is effective in localization of hyperplastic glands, underscoring the importance of routine bilateral neck exploration.
Collapse
Affiliation(s)
- V L Light
- Department of Surgery, Akron City Hospital, Ohio, USA
| | | | | | | | | |
Collapse
|
19
|
Abstract
To evaluate whether a prolonged infusion of Tc-99m sestamibi allows for visualization of viable myocardium in areas of hypoperfused myocardium, 25 patients were prospectively studied. Each patient was imaged four times in two consecutive days in the following manner: day 1:1) immediately after injection of Tl-201 at rest, 2) 1 hour after a bolus injection of Tc-99m sestamibi at rest; and day 2: 1) imaging in the Tl-201 window for 24 hour redistribution, 2) imaging after a 1-hour infusion of Tc-99m sestamibi. The two Tc-99m sestamibi and two Tl-201 studies were evaluated for presence of redistribution. This was present both on the Tl-201 and Tc-99m sestamibi studies (concordant) in 13 cases, and absent on both the Tl-201 and Tc-99m sestamibi studies (concordant) in 9 cases. In two cases redistribution was seen on the Tl-201 images only, and in one case it was seen on the Tc-99m sestamibi images only (discordant). Tc-99m sestamibi infusion may provide information about the presence of viable myocardium which is similar to that provided by Tl-201 24-hour imaging.
Collapse
Affiliation(s)
- S D Miron
- Department of Radiology, MetroHealth Medical Center, Cleveland, OH 44109-1998, USA
| | | | | | | | | |
Collapse
|
20
|
Affiliation(s)
- R Shah
- Department of Radiology, MetroHealth Medical Center/Case Western Reserve School of Medicine, Cleveland, OH 44109-1198
| | | | | |
Collapse
|
21
|
Sodee DB. Comparison of 99mTc-pertechnetate and 197Hg-chlormerodrin for brain scanning. J Nucl Med 1968; 9:645. [PMID: 5729215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
|
22
|
Razzak MA, Sodee DB. Radioisotope photoscanning of the salivary glands. Am J Gastroenterol 1968; 49:503-5. [PMID: 5662505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
23
|
Sodee DB. Eficacy of routine pancreatic scanning. Am J Gastroenterol 1967; 48:211-5. [PMID: 6079703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
24
|
Sodee DB. Radioisotope scanning of pancreas. N Y State J Med 1967; 67:2325-7. [PMID: 5234044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
25
|
Sodee DB. Pancreatic scanning. Geriatrics (Basel) 1967; 22:133-8. [PMID: 6027043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
26
|
Sodee DB. Combination scanning procedures in the evaluation of bronchogenic carcinoma. J Nucl Med 1967; 8:25-34. [PMID: 6019135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
27
|
|
28
|
|
29
|
Sodee DB. Brain scanning. Ohio State Med J 1966; 62:798-804. [PMID: 5946212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
30
|
Sodee DB. The clinical correlation of isotope pancreatography. Am J Gastroenterol 1966; 45:454-9. [PMID: 4951408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
31
|
|
32
|
|
33
|
|